MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.mayocp.2020.05.011

Медицинская библиотека · Mayo Clinic proceedings · 2020

SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review.

Narang Kavita, Enninga Elizabeth Ann L, Gunaratne Madugodaralalage D S K, Ibirogba Eniola R, Trad Ayssa Teles A, Elrefaei Amro, Theiler Regan N, Ruano Rodrigo, Szymanski Linda M, Chakraborty Rana, Garovic Vesna D

СтатьяПоддержка NIH: внешняя программаОбзорПеревод в очереди

Аннотация

The global pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), has been associated with worse outcomes in several patient populations, including the elderly and those with chronic comorbidities. Data from previous pandemics and seasonal influenza suggest that pregnant women may be at increased risk for infection-associated morbidity and mortality. Physiologic changes in normal pregnancy and metabolic and vascular changes in high-risk pregnancies may affect the pathogenesis or exacerbate the clinical presentation of COVID-19. Specifically, SARS-CoV-2 enters the cell via the angiotensin-converting enzyme 2 (ACE2) receptor, which is upregulated in normal pregnancy. Upregulation of ACE2 mediates conversion of angiotensin II (vasoconstrictor) to angiotensin-(1-7) (vasodilator) and contributes to relatively low blood pressures, despite upregulation of other components of the renin-angiotensin-aldosterone system. As a result of higher ACE2 expression, pregnant women may be at elevated risk for complications from SARS-CoV-2 infection. Upon binding to ACE2, SARS-CoV-2 causes its downregulation, thus lowering angiotensin-(1-7) levels, which can mimic/worsen the vasoconstriction, inflammation, and pro-coagulopathic effects that occur in preeclampsia. Indeed, early reports suggest that, among other adverse outcomes, preeclampsia may be more common in pregnant women with COVID-19. Medical therapy, during pregnancy and breastfeeding, relies on medications with proven safety, but safety data are often missing for medications in the early stages of clinical trials. We summarize guidelines for medical/obstetric care and outline future directions for optimization of treatment and preventive strategies for pregnant patients with COVID-19 with the understanding that relevant data are limited and rapidly changing.

Для цитирования: Narang Kavita, Enninga Elizabeth Ann L, Gunaratne Madugodaralalage D S K, Ibirogba Eniola R, Trad Ayssa Teles A, Elrefaei Amro, Theiler Regan N, Ruano Rodrigo, Szymanski Linda M, Chakraborty Rana, Garovic Vesna D. SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review.. Mayo Clinic proceedings. 2020. DOI: 10.1016/j.mayocp.2020.05.011.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.